Related Experiment Video

Updated: May 21, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

Vandetanib for the treatment of lung cancer

Caleb T Chu1, Yvonne H Sada, Edward S Kim

  • 1The University of Texas MD Anderson Cancer Center, Department of Thoracic/Head and Neck Medical Oncology, 1515 Holcombe Boulevard, Box 432, Houston, TX 77030, USA.

Expert Opinion on Investigational Drugs
|June 7, 2012
PubMed
Abstract

Insights

Dual inhibition of VEGF and EGFR shows promise for non-small cell lung cancer (NSCLC) therapy. Vandetanib, while not yet approved for NSCLC, demonstrates potential based on its efficacy in other cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) are key targets in non-small cell lung cancer (NSCLC).
  • VEGF and EGFR signaling pathways are interconnected, suggesting combined inhibition could enhance therapeutic effects.
  • Molecules like vandetanib inhibit multiple kinases, including VEGFR and EGFR, with potential applications in solid tumors.

Purpose of the Study:

  • To review the significance of targeting VEGF and EGFR in NSCLC treatment.
  • To explore the rationale for dual inhibition of VEGF and EGFR.
  • To examine clinical trials of vandetanib in refractory NSCLC.

Main Methods:

  • Literature review of targeted therapy in NSCLC.
  • Analysis of dual signaling inhibition strategies.
  • Exploration of clinical trial data for vandetanib.

Main Results:

  • Dual inhibition of VEGF and EGFR pathways is a promising strategy for NSCLC.
  • Vandetanib exhibits inhibitory effects on VEGFR, EGFR, and other kinases.
  • Clinical trials investigate vandetanib's efficacy in refractory NSCLC.

Conclusions:

  • Vandetanib is not currently approved for NSCLC treatment.
  • Its approval for medullary thyroid cancer suggests potential for identifying responsive NSCLC patient populations.
  • Further research may identify biomarkers to guide vandetanib therapy in NSCLC.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...